|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 11 (December 1), 1998:
pp. 4003-4012
RAPID COMMUNICATION
The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks
Transforming Growth Factor- -Mediated Growth Inhibition of Myeloid
Cells
Mineo Kurokawa,
Kinuko Mitani,
Yoichi Imai,
Seishi Ogawa,
Yoshio Yazaki, and
Hisamaru Hirai
From the Department of Hematology & Oncology, Graduate School of
Medicine, University of Tokyo, Tokyo, Japan.
The t(3;21)(q26;q22) chromosomal translocation associated with
blastic crisis of chronic myelogenous leukemia results in the formation
of the AML1/Evi-1 chimeric protein, which is thought to play a
causative role in leukemic transformation of hematopoietic cells. Here
we show that AML1/Evi-1 represses growth-inhibitory signaling by
transforming growth factor- (TGF-) in 32Dcl3 myeloid cells. The
activity of AML1/Evi-1 to repress TGF- signaling depends on the two
separate regions of the Evi-1 portion, one of which is the first zinc
finger domain. AML1/Evi-1 interacts with Smad3, an intracellular
mediator of TGF- signaling, through the first zinc finger domain,
and represses the Smad3 activity, as Evi-1 does. We also show that
suppression of endogenous Evi-1 in leukemic cells carrying inv(3)
restores TGF- responsiveness. Taken together, AML1/Evi-1 acts as an
inhibitor of TGF- signaling by interfering with Smad3 through the
Evi-1 portion, and both AML1/Evi-1 and Evi-1 repress TGF--mediated
growth suppression in hematopoietic cells. Thus, AML1/Evi-1 may
contribute to leukemogenesis by specifically blocking growth-inhibitory
signaling of TGF- in the t(3;21) leukemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Lugthart, E. van Drunen, Y. van Norden, A. van Hoven, C. A. J. Erpelinck, P. J. M. Valk, H. B. Beverloo, B. Lowenberg, and R. Delwel
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
Blood,
April 15, 2008;
111(8):
4329 - 4337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Blum, R. B. Klisovic, B. Hackanson, Z. Liu, S. Liu, H. Devine, T. Vukosavljevic, L. Huynh, G. Lozanski, C. Kefauver, et al.
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
J. Clin. Oncol.,
September 1, 2007;
25(25):
3884 - 3891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dong and G. C. Blobe
Role of transforming growth factor-beta in hematologic malignancies
Blood,
June 15, 2006;
107(12):
4589 - 4596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Maki, T. Yamagata, T. Asai, I. Yamazaki, H. Oda, H. Hirai, and K. Mitani
Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos
Blood,
September 15, 2005;
106(6):
2147 - 2155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F.J.D. Benus, A. T.J. Wierenga, D. J.J. de Gorter, J. J. Schuringa, A. M. van Bennekum, L. Drenth-Diephuis, E. Vellenga, and B. J.L. Eggen
Inhibition of the Transforming Growth Factor {beta} (TGF{beta}) Pathway by Interleukin-1{beta} Is Mediated through TGF{beta}-activated Kinase 1 Phosphorylation of SMAD3
Mol. Biol. Cell,
August 1, 2005;
16(8):
3501 - 3510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Sakoda, Y. Gotoh, H. Katagiri, M. Kurokawa, H. Ono, Y. Onishi, M. Anai, T. Ogihara, M. Fujishiro, Y. Fukushima, et al.
Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity
J. Biol. Chem.,
July 3, 2003;
278(28):
25802 - 25807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Jeruss, C. D. Sturgis, A. W. Rademaker, and T. K. Woodruff
Down-Regulation of Activin, Activin Receptors, and Smads in High-Grade Breast Cancer
Cancer Res.,
July 1, 2003;
63(13):
3783 - 3790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Liu, Y. Sun, F. Jiang, S. Zhang, Y. Wu, Y. Lan, X. Yang, and N. Mao
Disruption of Smad5 gene leads to enhanced proliferation of high-proliferative potential precursors during embryonic hematopoiesis
Blood,
January 1, 2003;
101(1):
124 - 133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Izutsu, M. Kurokawa, Y. Imai, K. Maki, K. Mitani, and H. Hirai
The corepressor CtBP interacts with Evi-1 to repress transforming growth factor {beta} signaling
Blood,
May 1, 2001;
97(9):
2815 - 2822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. O. Fortunel, A. Hatzfeld, and J. A. Hatzfeld
Transforming growth factor-beta : pleiotropic role in the regulation of hematopoiesis
Blood,
September 15, 2000;
96(6):
2022 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. de Caestecker, E. Piek, and A. B. Roberts
Role of Transforming Growth Factor-{beta} Signaling in Cancer
J Natl Cancer Inst,
September 6, 2000;
92(17):
1388 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jakubowiak, C. Pouponnot, F. Berguido, R. Frank, S. Mao, J. Massague, and S. D. Nimer
Inhibition of the Transforming Growth Factor beta 1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein
J. Biol. Chem.,
December 15, 2000;
275(51):
40282 - 40287.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
